Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.
AffiliationDepartment of Ophthalmology, Mid-Western Regional Hospital, Dooradoyle, Limerick. email@example.com
MetadataShow full item record
CitationIntravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. 2011, 104 (5):146-9 Ir Med J
JournalIrish medical journal
AbstractThe purpose of this study was to compare the vascular event rate in AMD patients treated with an intravitreal VEGF inhibitor with a historical control group treated with photodynamic therapy. We reviewed medical records of 83 patients treated with intravitreal anti-VEGF for AMD between 2005-2007, and 60 patients treated with PDT between 2001-2004. Mean follow-up in the anti-VEGF group was 40 months versus 95 months in the PDT group. Mean age (76 +/- 9 years, versus 74 +/- 10 years, p=n.s.) and cardiovascular risk factor profile were similar. Vascular event rates in each group were 2.6 per 100 patient years versus 2.3 per 100 patient years, (p = n.s). Age over 80 years was associated with an increased risk of a vascular event (odds ratio = 1.113, p<0.05). Despite the high prevalence of risk factors in AMD patients, the incidence of vascular events was low and associated with older age rather than therapy received.
- Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
- Authors: Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A
- Issue date: 2007 Apr-May
- Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
- Authors: Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH
- Issue date: 2014 Sep
- Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
- Authors: Lee SJ, Koh HJ
- Issue date: 2011 Jan
- [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
- Authors: Karel I
- Issue date: 2007 Sep
- Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
- Authors: Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS
- Issue date: 2012 Aug